Navigation Links
New drug protects against side effects of chemotherapy
Date:1/22/2013

A drug developed at Linkping University in Sweden protects against the side effects of cancer treatments while strengthening the effects on the tumour. An international drug evaluation is now starting up on a larger group of patients.

The results of the studies with the compound, known as calmangafodipir, were published in the latest issue of the cancer journal Translational Oncology with Professor Rolf G. G. Andersson as the main author. The research was initiated on a substance called mangafodipir, which was used as a contrast media in magnetic resonance scans. But pharmacologists at LiU discovered that it also protected healthy cells in connection with cancer treatments.

"We found that the substance could affect the formation of oxygen radicals, which are a cause of side effects in chemotherapy," says Professor Andersson. For example, the number of white blood cells decreases drastically in almost all the patients, which opens the door to infections that could even be fatal.

The researchers began with cell tests, and then went on to mice infected with cancer cells. The mice were treated with chemotherapy and were administered mangafodipir at the same time. Tumour formation decreased while white blood cells were protected. One problem was that a large portion of the manganese in the substance was released; as a consequence, the positive effect subsided. The free manganese can also be poisonous and cause brain damage.

"We remade the substance and replaced a lot of the manganese with calcium. This yielded a more stable complex, which turned out to be even better at protecting cells, thereby increasing the anti-cancer effect," says Professor Andersson. The effect of mangafodipir was confirmed in a smaller study on patients with colon cancer, which was published in Translational Oncology in February 2012.

Jan Olof G. Karlsson is a senior lecturer at Linkping University and a senior researcher at PledPharma AB who is developing the drug, which will be marketed under the brand name PledOx. An international Phase 2 study, involving patients with cancer of the large intestine, has recently been initiated. The results are expected at the end of the year.


'/>"/>

Contact: Rolf G.G. Andersson
rolf.andersson@liu.se
46-070-237-1080
Linkping University
Source:Eurekalert

Related medicine news :

1. Minimal Exercise Protects Senior’s Hearts According to Recent Study Reviewed By Projects for Natural Health Choices Inc.
2. High levels of vitamin D in plasma protects against bladder cancer
3. Aspirin protects against Barretts esophagus
4. Broken heart syndrome protects the heart from adrenaline overload
5. Vitamin E in diet protects against many cancers
6. Voices Against Brain Cancer Responds to a Mother’s Successful Fight Against her Glioblastoma
7. To protect against injuries, young athletes may need to play more just for fun
8. More Focused Radiation Treatment May Work Better Against Brain Tumors
9. Vapor Steam Cleaners Help Protect Puppies Against Canine Parvovirus Disease, Announces 1-800-GO-VAPOR.com
10. Going Online for Info May Reflect a Pro-Active Stance Against Cancer
11. FDA Panel Recommends Against 1st Drug for Chronic Fatigue Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2017)... ... July 23, 2017 , ... ... Pain Relief Group – Melbourne, a practice owned by Physician Partners of America ... pain management, Dr. Stern also is certified in pediatrics, emergency medicine and anesthesiology. ...
(Date:7/23/2017)... ... July 23, 2017 , ... Viora Ltd., a leading ... Patent No. 9,038,640 by the United States Patent and Trademark Office. The patent ... of Switching, Vacuum, and Cooling mechanisms to further increase the efficacy and safety ...
(Date:7/22/2017)... ... July 22, 2017 , ... More than 130,000 Anterior Cruciate ... requiring pain medication after three months post-operatively. However, researchers presenting their work at ... Toronto, Ontario, Canada found that those patients who were filling opioid prescriptions prior ...
(Date:7/21/2017)... ... 21, 2017 , ... "As a doctor of lung medicine managing chest diseases ... the market," said an inventor from Center Valley, Pa. "My idea is to improve ... He developed the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an efficient means of ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... and financial consultations to communities in the greater Denver region, is announcing a ... diagnosed with a very rare kind of epilepsy. , Until a few months ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
(Date:6/30/2017)... SAN DIEGO , June 30, 2017  AVACEN Medical (AVACEN) ... Access Journal. The research describes the use of its AVACEN ... by those suffering from fibromyalgia. ... AVACEN Medical ... Fibromyalgia is characterized by chronic widespread pain. It affects approximately 200 to ...
(Date:6/27/2017)... , Jun 27, 2017   NuEyes (NuEyes ... of funding to fuel its growth in helping the legally ... (Osterhout Design Group), the leading developer of augmented, virtual ... technology sits. The undisclosed funding amount was provided ... firm, Arab Angel, with offices in Abu Dhabi ...
Breaking Medicine Technology: